Novavax, Serum Institute plans to supply 1.1 billion doses to COVAX

Novavax has signed a memorandum of understanding (MoU) in this regard with Gavi, the Vaccine Alliance.

Photo: Bloomberg

The vaccine doses of NVX-CoV2373 will be manufactured and distributed globally by SII and Novavax.

Sohini Das Mumbai
US-based vaccine major Novavax on Friday said along with its Indian partner Serum Institute of India (SII) it would supply 1.1 billion doses of Covid vaccine to Gavi-led COVAX.
The vaccine candidate NVX-CoV2373 has demonstrated clinical efficacy against the original Covid-19 strain and both of the rapidly emerging variants in the UK and South Africa.

Also Read

The story behind the rise of Serum Institute, world's vaccine factory

A jab at risk: Serum's quest to lead the world in Covid-19 vaccine race

We are researching two candidates for Covid vaccines: Serum Institute CEO

Repurposing capacity for Covid-19 vaccine, say Indian pharma firms

Serum Institute may supply around 400 million more doses to Gavi-Covax

Covid-19 vaccination: Serum Institute to gain from G7's boost to COVAX

Dr Reddy's applies for emergency use approval for Sputnik V vaccine

Amazon India signs agreement with DGR for hiring ex-service personnel

Sustainability can help companies become more profitable: Accenture CEO

Dhunseri, Berger may invest Rs 500 cr in Bengal's Panagarh industrial park

First Published: Feb 19 2021 | 11:12 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to